Frost & Sullivan: Health Information Exchange Systems are Critical to the Integration of Healthcare Services

LONDON, July 22, 2014 /PRNewswire/ — The need to contain hospital operational costs, improve workflow efficiency, and to provide better access to healthcare, has led to the integration of healthcare services. In turn, integrated systems have supported the development of innovative and patient-centric delivery models such as patient-centred medical homes and care-at-a-distance solutions. A strong information system infrastructure will further facilitate affordable, accountable and integrated delivery of services along the continuum of care.

Photo – http://photos.prnewswire.com/prnh/20140722/129167

New analysis from Frost & Sullivan, Technologies Enabling Home Medical Devices and Integrated Care Systems, finds that health information exchange (HIE) systems are a key technological driver of new healthcare models. HIE refers to the digitisation of health records to create a central data repository that will ensure continuity of care, data legacy and data-drive health analytics.

Ongoing and imminent changes to regulatory and legislative policies pertaining to healthcare delivery, such as incentivising electronic information sharing and mandating meaningful use of patient health data, will encourage the adoption of information systems like HIE in many countries.

“These changes are likely to have far-reaching consequences for healthcare delivery, particularly in predictive diagnosis and population health management,” said Technical Insights Research Analyst Bhargav Rajan. “Instead of functioning merely as workflow aids, information systems are likely to transform the very nature of healthcare planning and delivery, ushering in predictive analytics and coordinated care management.”

One challenge to the adoption of technological frameworks is the fragmentation of the healthcare market in several countries, causing interoperability issues. Healthcare providers are also unwilling to make the high initial investment required for these systems.

Technology providers need to design systems-agnostic solutions that can be used across technology platforms in order to allay client concerns about interoperability and compatibility. Healthcare providers too must gauge and understand the value information systems bring to their practice in effecting affordable, quality service in line with patient needs.

“A fully functional, integrated healthcare system is a product of innovations in technology, management and implementation,” noted Rajan. “Of these, a solid technological infrastructure, led by dynamic and interactive information systems, will be key in establishing home and integrated care systems.”

If you are interested in more information on this study, please email Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

Technologies Enabling Home Medical Devices and Integrated Care Systems, a part of the Technical Insights subscription, provides a holistic analysis of the various component technologies in integrated healthcare systems. The study highlights key technologies and industry forces that enable integrated healthcare delivery, with the goal of aiding technology and service providers in identifying disruptive innovations opportunities in this space. Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging

MOUNTAIN VIEW, Calif., July 22, 2014 /PRNewswire/ — Based on its recent analysis of the magnetic resonance imaging (MRI) market, Frost & Sullivan recognizes Siemens Healthcare with the 2014 North American Award for Product Leadership. Siemens Healthcare’s FREEZEit solution, which employs Siemens’ MAGNETOM Aera and Skyra scanners, addresses the need for robust and motion-insensitive imaging. The solution’s sophistication and utility in patient care has boosted the evolution of body MRI imaging in the U.S. market.

“Currently, body MR imaging, which is the imaging of the chest, abdomen and pelvis, represents about 10 percent of the MR imaging procedure volume; yet some institutions have experienced a tripling of body referrals within a few years,” said Frost & Sullivan Principal Analyst Nadim Daher. “One of the reasons for their growth was the delivery of rapid, consistent exams that patients could complete even with limited breath-holding capabilities.”

Conventional MR imaging is sensitive to motion, whether voluntary (respiratory motion or physical movement by the patient) or involuntary (cardiac motion, bowel motion). Body MR imaging also requires the patient to hold their breath in order to achieve diagnostic image quality; however, children, the elderly or very sick patients find it difficult to comply with the breath-hold commands. Traditional systems also need robust fat suppression to amplify the conspicuity of the vessels and lesions. Furthermore, contrast timing is vital for the characterization of lesions by these systems.

StarVIBE and TWIST-VIBE, the two components of FREEZEit, enable providers to overcome these challenges and expand their body MR referrals beyond computed tomography, the preferred modality up to this point. Referring physicians now have the opportunity to choose imaging modalities without radiation doses, especially in cases such as hemangiomas, focal nodular hyperplasia (FNH) and benign adenomas, which need repeat exams throughout the lifetime of the patient.

StarVIBE intelligently resists motion artifacts and, therefore, facilitates free-breathing 3D T1 exams. This will allow for much faster exams and fewer repeat scans, which, in turn, will enable providers to schedule patients for shorter slots, enhance the utilization rate of their equipment and, ultimately, increase their revenue.

Meanwhile, TWIST-VIBE provides dynamic liver imaging with high temporal and spatial resolution and full 4D coverage. It catches the precise point of the arterial phase when using contrast so that even almost invisible liver lesions can be detected. This technology has an immediate impact on treatment decisions, saving time and costs for caregivers and patients.

“Siemens realized MRI’s untapped potential in body applications and is truly acting as a driver of progress in the MRI market,” noted Daher. “Its innovations have had a significant impact on patient care and can potentially help healthcare providers improve their efficiency and lower their costs.”

The company has leveraged technology innovation, product excellence and quality of service to advance clinical and patient outcomes, while enhancing the overall value and cost-efficiency of care. In recognition, Frost & Sullivan is pleased to present the 2014 Product Leadership Award to Siemens Healthcare.

Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

Contact:

Mireya Espinoza
P: +1-210.247.3870
F: +1-210.348.1003
E: mireya.espinoza@frost.com

Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices

NORTHBROOK, Ill., July 22, 2014 /PRNewswire/ — UL (Underwriters Laboratories), a global safety science leader, has announced that the U.S. Food and Drug Administration (FDA) has recognized two UL battery safety standards as consensus standards for medical devices incorporating lithium or nickel-based batteries. The two standards are UL 2054 – Standard for Household and Commercial Batteries, and UL 1642 – Standard for Lithium Batteries (Cells).

Logo – http://photos.prnewswire.com/prnh/20140721/129100

Consensus standards are standards recognized by the FDA for use in evaluating medical devices before they are approved for market entry. The FDA’s Center for Devices and Radiological Health (CDRH) believes that conformance with recognized consensus standards can support a reasonable assurance of safety and/or effectiveness for many applicable aspects of medical devices. In the case of medical devices using batteries, manufacturers can now use the proof of compliance with UL 2054 and UL 1642 as evidence of a device’s safety and effectiveness.

According to Ibrahim Jilani, Battery Manager for UL’s Consumer Technology Division, consensus standards are also a means to streamline the premarket review process. “The use of these recognized standards will not only help medical device manufacturers reduce regulatory obstacles to enter the U.S. and international markets but also help them satisfy FDA premarket review requirements.”

Although certification is voluntary, UL anticipates this announcement will likely be a sizeable regulatory driver going forward whereby medical device manufacturers will look to have UL 2054 Compliant Nickel Cell Type(s), UL 1642 Compliant Lithium Cell Type(s), and/or UL 2054 Compliant Battery Pack(s).

“UL has more than 30 years of experience in battery standard development, safety and performance testing, fostering innovation in the industry and boosting confidence in battery quality,” said Jilani. “We believe both medical device manufacturers and consumers will benefit from products evaluated to UL’s battery safety standards in the United States and markets worldwide.”

For more information about UL’s battery testing & certification, visit http://www.ul.com/batt  and/or http://www.ul.com/largebatt for large format batteries.

About UL
UL is a premier global independent safety science company that has championed progress for 120 years. Its more than 10,000 professionals are guided by the UL mission to promote safe working and living environments for all people. UL uses research and standards to continually advance and meet ever-evolving safety needs. We partner with businesses, manufacturers, trade associations and international regulatory authorities to bring solutions to a more complex global supply chain. For more information about our certification, testing, inspection, advisory and education services, visit http://www.UL.com .

CONTACT: Richard Hammer
Marketing Manager
UL LLC
T: +1-510-771-1000 ext. 53125

$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research

CAMBRIDGE, Mass., July 22, 2014 /PRNewswire/ — The Broad Institute today announced an unprecedented commitment of $650 million from philanthropist Ted Stanley aimed at galvanizing scientific research on psychiatric disorders and bringing new treatments based on molecular understanding to hundreds of millions of people around the world.

The Stanley commitment – the largest ever in psychiatric research and among the largest for scientific research in general – will support research by a collaborative network of researchers within the Stanley Center for Psychiatric Research at the Broad Institute, a biomedical research institution that brings together faculty from MIT, Harvard University, the Harvard-affiliated hospitals, and collaborators worldwide.

Stanley’s commitment to support the work of the Broad Institute will consist of annual gifts during his lifetime followed by a bequest, with a total current value exceeding $650 million. Taking prior gifts into account, Stanley’s philanthropy in support of the Broad Institute’s work totals more than $825 million.

The biological causes of mental illnesses such as schizophrenia and bipolar disorder have mystified scientists for decades; in the last five years, however, understanding has accelerated dramatically, driven by advances in human genomics. Because researchers cannot study the biochemistry of the living human brain, the genes that predispose people to schizophrenia and bipolar disorder represent the best way to gain molecular insights into these disorders. The discovery of specific genes associated with these disorders provides significant clues to their biological basis and points to possible molecular targets for novel therapies.

Since 2004, Ted Stanley and his late wife, Vada Stanley, have been instrumental to the progress made thus far in identifying the genetic risk factors for schizophrenia and bipolar disorder and the initiation of therapeutic efforts based on those discoveries. Their gifts made possible the establishment of the Stanley Center at the Broad Institute in 2007 and helped support an international collaboration that today involves scientists in 25 countries. Stanley’s new commitment is the culmination of a 25-year personal mission to discover the biology of psychiatric disorders and lay the groundwork for effective therapies.

“Human genomics has begun to reveal the causes of these disorders. We still have a long way to go, but for the first time we can point to specific genes and biological processes. It’s now time to step on the gas pedal,” Stanley said. “I am devoting my personal wealth to this goal. But it will take all of us – philanthropists, government funding agencies, scientists, patients, and families – working together to achieve it.”

“This is a pivotal moment,” said Thomas Insel, director of the National Institute of Mental Health (NIMH) at the National Institutes of Health (NIH). “We are finally beginning to gain the deep knowledge about these disorders that we have sought for decades.”

Years of frustration give way to progress

Mental illness exacts an enormous human toll. The leading cause of disability in the United States, it affects millions and most often strikes patients while they are young and otherwise healthy. Biomedical researchers have struggled for years to understand the molecular causes of serious ailments such as schizophrenia and bipolar disorder. Until five years ago, there was no clear scientific evidence around even a single gene that contributes to causing either disorder.

Research to develop new treatments has also stalled. No fundamentally new drugs have been introduced since the 1950s. All but a handful of pharmaceutical companies have abandoned the pursuit of new treatments because the basic science has seemed intractable.

Yet in the past few years, scientists have begun to find genes that shape the risk of schizophrenia, bipolar disorder, and other illnesses – thanks in large part to Stanley’s support. Researchers at the Broad Institute have harnessed DNA mapping and sequencing technology, supported collaborative networks of researchers from more than 60 institutions in 25 countries, and assembled the world’s largest collection of DNA samples in psychiatric research — currently at over 175,000 samples — including schizophrenia, bipolar disorder, autism, attention deficit hyperactivity disorder (ADHD), and healthy control samples. Analysis of 80,000 of these samples so far by Broad researchers and collaborators has linked more than 100 genomic regions to schizophrenia and begun to identify specific gene mutations and the critical underlying biological processes, such as an impaired ability of neurons to communicate with each other. Significant efforts are ramping up in bipolar disorder, autism, and other conditions.

“We are going to illuminate the biology behind these conditions,” said Eric Lander, founding director and president of the Broad Institute. “If we know the biological causes, we can begin to dispel the stigma around people battling mental illness, and rigorously pursue better treatments that will transform patients’ lives.”

[For more information, see backgrounder on Genomics: Reinvigorating the field of psychiatric research]

Three lives converge on a shared scientific mission

This scientific success – and the historic commitment of funding announced today – stems, in large part, from the devotion of three extraordinary people whose lives converged at the Broad Institute.

Stanley’s passion for the cause began decades ago when his son, Jonathan, was stricken with severe bipolar disorder while in college. The first few years were difficult, but Jonathan overcame his illness with the help of lithium, a landmark drug first used to treat patients with mental illness in 1949. Now a successful attorney, Jonathan is also a founding board member of the Treatment Advocacy Center, a nonprofit organization dedicated to reforming laws that affect persons with a mental illness, and an advocate for NAMI, the National Alliance on Mental Illness. Although lithium helped give Jonathan a normal life, other patients who suffer from mental illness have not been as fortunate. Hoping to help these patients, Ted and Vada Stanley went on to found the Stanley Medical Research Institute in 1989, aimed at finding treatments that would be as effective for others as lithium has been for their son.

When Edward Scolnick met the Stanleys, he had had a stellar career, first in cancer research in the 1970s and then as one of the most respected scientists in the pharmaceutical industry. As president of Merck Research Laboratories, Scolnick led the development of the first drugs to effectively combat HIV; the first drugs to effectively treat high cholesterol, statins; the first vaccine against cervical cancer; and many other breakthroughs. Instead of retiring, Scolnick took on a new challenge – he moved to the Broad Institute to tackle mental illness because he had a deep personal interest in the field. Early in his career, Scolnick had helped launch a revolution in cancer research based on the discovery of the first cancer genes. He wanted to set psychiatric research on the same path.

Scolnick vividly remembers the moment he and the Stanleys joined forces. He told them, “If you want to get at the molecular pathogenesis of these disorders, you’ve got to crack the genetics. That’s what has held this field back for so long.”

The Stanleys had given many small grants to support psychiatric research through their foundation, but Scolnick argued for the importance of critical mass – and asked them to contribute $10 million to launch a program at the Broad Institute. Ted Stanley agreed, and after clear initial progress called Scolnick back with a new proposal: “Let’s do something bigger. How about we give you $100 million over ten years?” Thus, the Stanley Center for Psychiatric Research at the Broad was launched in 2007, with Scolnick as its founding director.

The third player was Steven Hyman, who at the time was provost at Harvard University. Before taking that post, Hyman, a psychiatrist, had served as head of the National Institute of Mental Health (NIMH) from 1996 to 2001. (Scolnick served as a member of Hyman’s National Advisory Mental Health Council from 1998 to 2002, and Lander served as a member of the NIMH’s Genetics Workgroup, and the three had developed a mutual respect and a shared vision for what was needed in the field.) As director, Hyman led the NIMH to invest in both neuroscience and genetics, and, along with Scolnick and Lander, supported the collection of DNA samples from patients, with the hope that the samples could someday be analyzed to find disease genes. But progress was slow, partly because the Human Genome Project had not yet been completed. When Hyman left the NIMH in 2001 to become provost of Harvard University, he had almost completely lost hope that true progress could be made in his lifetime in elucidating the mechanisms of psychiatric illness.

Hyman helped launch the Broad Institute of MIT and Harvard in 2004 and, over time, became encouraged by the Broad’s progress in the molecular understanding of psychiatric disorders. After nine years as Harvard Provost, he joined the Broad and then became the director of the Stanley Center in 2012.

“Ten years ago, finding the biological causes of psychiatric disorders was like trying to climb a wall with no footholds,” said Hyman. “But in the last few years, we’ve turned this featureless landscape into something we can exploit. If this is a wall, we’ve put toeholds into it. Now, we have to start climbing.”

[For more information, see backgrounder on Shared Vision: Three lives converge to revitalize mental health research]

A unique and powerful research model

The Stanley Center’s rapid progress was possible only because of the unique nature of the Broad Institute, its home institution. The Broad Institute grew from an MIT-based flagship center for the Human Genome Project, and generated a third of the DNA sequence data for that project – the single largest contribution to the effort. Formally founded in 2004 to fulfill the promise of the Human Genome Project by facilitating collaborative biomedical research across disciplines and institutions, it brings together faculty from Harvard University, the Massachusetts Institute of Technology, and the five major Harvard-affiliated hospitals: Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital. Celebrating its tenth anniversary in July, the Broad Institute is today home to a community of more than 2,000 members, including physicians, biologists, chemists, computer scientists, engineers, staff, and representatives of many other disciplines. Together, the Broad Institute community uses industrial-strength technological capabilities to take on challenges too great for any single lab or institution to tackle.

Broad investigators have led international consortia that have found thousands of genetic variants responsible for common diseases such as diabetes, heart disease, and Crohn’s disease – and translated that knowledge into descriptions of the underlying biological processes, a critical step in the development of rationally designed drugs. They have discovered several hundred genes that are mutated in cancer and applied this knowledge to begin to invent new, targeted forms of therapy. Broad scientists have also invented powerful new tools that allow researchers to precisely manipulate the genome and measure the millions of complex chemical interactions within cells. In the spirit of the Human Genome Project, the Broad makes its genomic data freely available to researchers around the world.

The future of psychiatric research

The Stanley Center engages a community of more than 150 scientists at the Broad Institute and its partner institutions. Over the coming years, the center plans to draw on Stanley’s tremendous generosity to accomplish at least four major goals:

(i) Complete the list of all genes that play roles in severe psychiatric disorders, including schizophrenia, bipolar disorder, autism, and others. To create a comprehensive catalog of the genetic variation that underlies mental illness, the researchers plan to expand their international network and draw in many more collaborators with new insights and capabilities. They also plan to expand their sample collection efforts dramatically – especially among understudied populations, such as those in African nations – to reveal the many as-yet-undiscovered mutations relevant to disease. As a first step, they plan to carry out comprehensive analysis of all genes that specify the protein building blocks of cells from 100,000 samples in the next two years.

(ii) Reveal the biological pathways in which these genes act. To do so, they will push technological boundaries, working with new techniques that allow them to manipulate and comprehensively measure the dynamic activity of genes in living cells, including lab-grown neurons produced by new stem-cell technologies. Their ultimate, ambitious goal: to determine where, when, and how these genes act in human brain cells, and how in psychiatric patients those processes may go awry.

(iii) Develop cellular and animal models that faithfully mimic human disorders. In contrast to researchers studying cancer or diabetes, researchers studying psychiatric disorders have been unable to identify animal models that correctly capture important biological aspects of the disorders and correctly predict which therapies will be effective in humans. Now, with growing knowledge of the genes underlying psychiatric disorders, Broad researchers plan to create cellular models in the laboratory and animal models that more faithfully match both the genetic variation and the biochemical processes seen in human patients. They plan to pioneer cutting-edge techniques such as genome editing, which allows them to precisely introduce any mutations they choose.

(iv) Develop chemicals to modulate biological pathways to serve as drug leads. The researchers plan to build on the existing therapeutic efforts within the Stanley Center and draw on the Broad’s Therapeutics Platform – a technological powerhouse with the capacity to create and screen hundreds of thousands of compounds – to identify molecules that can powerfully and precisely influence specific biological pathways relevant to psychiatric disorders. They then plan to comprehensively investigate those chemicals’ effects to determine which of them might serve as promising leads for drugs that could be safely and effectively used in humans.

“We’re still at the beginning of the curve of translating the emerging genetics into actionable biology, but it’s happening much faster than I thought it would,” said Scolnick. “I’d be bold enough to say that in five years, all the drug companies that got out of psychiatric research will be getting back in. The coming decades of psychiatric research will yield new science and a needed parallel effort to increase resources for services that can help patients and their families.”

R&D To Develop Cost Effective Products Will Be Crucial in the ANZ RFID Market, Says Frost & Sullivan

SYDNEY, July 22, 2014 /PRNewswire/ — The need to optimise business processes is prompting organisations across Australia and New Zealand (ANZ) to adopt radio-frequency identification (RFID) solutions. The transport and logistics sector, in particular, has deployed these solutions for rail freight transport, truck tracking, and vehicle traffic management applications. Such implementations are expected to help increase awareness of RFID technology and, in turn, fuel deployments.

New analysis from Frost & Sullivan, Analysis of the ANZ RFID Market, finds that the market earned revenues of $33.0 million in 2013 and estimates this to reach $72.1 million in 2018 at a compound annual growth rate of 16.9 percent. The study covers the end-user segments of transport and logistics, livestock, healthcare and retail. Among these verticals, healthcare is likely to witness the highest growth during the forecast period.

“Currently, RFID solutions are used in the healthcare industry for applications such as patient monitoring, asset tracking and implant tracking,” said Frost & Sullivan Measurement & Instrumentation Research Analyst Vivek K Reghu. “However, with Australian hospitals expected to adopt ICT technologies to develop a fully integrated healthcare system by 2020, the application areas of RFID will expand.”

The implementation of mandatory livestock tracking programs across ANZ is driving the demand for RFID solutions that can help establish a national livestock identification system and improve the traceability of livestock. RFID adoption rates in the livestock industry will strengthen also due to a rising concern about the cost that would have to be incurred in the case of disease outbreaks. The Australian Bureau of Agricultural and Resource Economics and Sciences estimates that foot-and-mouth disease, for instance, could cost the Australian livestock sector around $50 billion over 10 years.

Nevertheless, many players in the livestock industry cannot afford to integrate RFID solutions. The New South Wales Department of Primary Industries estimates that the implementation of a RFID system could cost livestock owners approximately six percent of their gross profit. Besides cost, the existence of a robust infrastructure for barcode technology, especially in the retail sector, is discouraging the uptake of RFID. Uncertainty about the return on investment in RFID solutions and end users’ unwillingness to move away from the current technology they use are also slowing down market development.

“As price is the biggest challenge in this market, RFID vendors in ANZ need to focus on R&D to develop high-quality products that are cost effective,” pointed out Vivek. “They will do well to provide customised RFID solutions as opposed to off-the-shelf ones.”

For more information on this study, please email Donna Jeremiah, Corporate Communications, at djeremiah@frost.com.

Analysis of the ANZ RFID Market is part of the Automatic Identification (http://www.autoid.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Global 2D-Barcode Scanners Market, Global RFID in Manufacturing Market, Global RFID Tags Market, and Southeast Asia Radio Frequency Identification Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation

Analysis of the ANZ RFID Market
P793-11

Contact:
Donna Jeremiah
Corporate Communications – Asia Pacific
P: +61 (02) 8247 8927
F: +61 (02) 9252 8066
E: djeremiah@frost.com

http://www.frost.com